AEGR Aegerion Pharmaceuticals, Inc.

0.00
+0  (0%)
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap N/A
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 510,647

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Early approval Dec 24 2012
Lomitapide
Homozygous familial hypercholesterolemia (HoFH)

Latest News

  1. AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mater
  2. Aegerion Pharmaceuticals, Inc. and QLT Inc. Complete Merger Transaction; QLT to Change Name to Novelion Therapeutics Inc.
  3. Aegerion's Juxtapid Gets Pricing Authorization in Japan
  4. Aegerion Pharmaceuticals' JUXTAPID® (lomitapide) Capsules for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) Receives Pricing Authorization in Japan
  5. AEGERION PHARMACEUTICALS, INC. Financials
  6. ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : November 8, 2016
  7. AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  8. Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016
  9. Aegerion Pharmaceuticals Appoints John Orloff, M.D., as Executive Vice President, Head of R&D
  10. Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3
  11. AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
  12. Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial Results
  13. QLT's (QLTI) Reports In-Line Q3 Loss, Merger in Focus
  14. AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
  15. ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : October 20, 2016
  16. AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
  17. AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  18. Aegerion Pharmaceuticals' JUXTAPID® (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
  19. ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : September 27, 2016
  20. Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day